Umbilical cord blood transfusions for prevention of progressive brain injury and induction of neural recovery: An immunological perspective

Regenerative Medicine

Volumn 2, Issue 4, 2007, Pages 457-464

  Willing, Alison E ^a   Eve, David J ^a   Sanberg, Paul R ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Brain trauma; Cord blood; Stem cells; Stroke

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA;

ARTICLE; BLOOD TRANSFUSION; BRAIN INJURY; CD4+ CD25+ T LYMPHOCYTE; CELL MATURATION; CELL MIGRATION; CELLULAR IMMUNITY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DENDRITIC CELL; HUMAN; IMMUNE DEFICIENCY; INTERMETHOD COMPARISON; METHODOLOGY; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; STROKE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH2 CELL; TREATMENT OUTCOME; UMBILICAL CORD BLOOD;

ANIMALS; BLOOD TRANSFUSION; BRAIN INJURIES; FETAL BLOOD; HUMANS;

EID: 34548169602     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.2.4.457     Document Type: Article

References (67)

1. Reynolds BA, Weiss S: Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science255(5052), 1707-1710 (1992).
2. Bjugstad KB, Redmond D E Jr, Teng YD et al.: Neural stem cells implanted into MPTP-treated monkeys increase the size of endogenous tyrosine hydroxylase-positive cells found in the striatum: a return to control measures Cell Transplant. 14(4), 183-192 (2005).
3. Yasuhara T, Matsukawa N, Yu G et al.: Behavioral and histological characterization of intrahippocampel grafts of human bone marrow-derived multipotent progenitor cells in neonatal ratswith hypoxio-ischemic injury. Cell Transplant. 15(3), 231-238 (2006).
4. Nandoe RDS, Hurtado A,, Levi ADO, Grotenhuis A, Oudega M. Bone marrow stromal cells for repair of the spinal cord: towards clinical application. Cell. Transplant. 15(7), 563-577 (2006).
5. Syková E, Homola, Mazanec R et al.: Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant. 15(8/9), 675-687 (2006).
6. McLeod M, Hong M, Sen A et al.: Transplantation of bioreactor-produced neural stem cells into the rodent brain. Cell transplant. 15(8/9), 689-697 (2006).
7. Broxmeyer HE, Douglas GW, Hangoc G et al.: Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells Proc Natl Acad. Sci. USA 86(10), 3828-3832 (1989).
8. Broxmeyer HE: Biology of cord blood cells and future prospects for enhanced clinical benefit. Cytotherapy 7(3), 209-218 (2005).
9. Madlambayan G, Rogers I: Umbilical cord-derived stem cells for tissue therapy: current and future uses. Regen. Med. 1(6), 777-787 (2006).
10. Gluckman E, Broxmeyer HA, Auerbach AD et al.: Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N. Eng. J. Med. 321(17), 1174-1178 (1989).
11. Petropoulos D, Chan KW: Umbilical cord blood transplantation. Curr. Oncol. Rep. 7(6), 406-409 (2005)
12. Borlongen CV, Hadman M, Sanberg CD, Sanberg PR: CNS entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. Stroke 35(10), 2385-2389 (2004).
13. Lu D, Sanberg PR, Mahmood A et al.: Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury. Cell Transplant. 11(3), 275-281 (2002).
14. Saporta S, Kim JJ, Willing AE, Fu ES, Davis CD, Sanberg PR: Human umbilical cord blood stem cells infusion in spinal cord injury: engraftment and beneficial influence on behavior. J. Hematother. Stem Cell Res 12(3), 271-278 (2003).
15. Garbuzova-Davis S, Willing AE, Zigova T et al.: Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis distribution, migration, and differentiation. J. Hematother. Stem Cell Res 12(3), 255-270 (2003).
16. Garbuzova-Davis S, Willing AE, Desjarlais T, Sanberg CD, Sanberg PR: Transplantation of human umbilical cord blood cells benefits an animal model of Sanfilippo syndrome type B. Stem Cells Dev. 14(4), 384-394 (2005).
17. Kang K-S, Kim SW, Oh YH et al.: A 37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, with improved sensory perception and mobility, both functionally and morphologically: a case study. Cytotherapy 7(4), 368-373 (2005).
18. Garbuzova-Davis S, Willing AE, Saporta S et al.: Novel cell therapy approaches for brain repair. Prog Brain Res 157, 207-222 (2006).
19. El-Badri NS, Hakki A, Saporta S et al.: Cord blood mesenchymal stem cells potential use in neurological disorders Stem Cells Dev. 15(4), 497-506 (2006).
20. Vendrame M, Gemma C, de Mesquita D et al.: Anti-inflammatory effects of human cord blood oells in a rat model of stroke. Stem Cells Dev. 14, 595-604 (2005).
21. Vendrame M, Gemma C, Pennypacker KR et al.: Cord blood rescues stroke-induced changes in splenocyte phenotype and function. Exp. Neurol. 199(1), 191-200 (2006).
22. + cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J. Clin. Invest. 114(3), 330-338 (2004).
23. Vendrame M, Cassady CJ, Newcomb J et al.: Infusion of human umbilical cord blood cells in a rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct volume. Stroke 35, 2390-2395 (2004).
24. Willing AE, Lixian J, Milliken M et al.: Intravenous versus intrastriatal cord blood administration in a rodent model of stroke. J. Neurosci. Res 73(3), 296-307 (2003).
25. Willing AE, Vendrame M, Mallery J et al.: Mobilized peripheral blood cells administered intravenously produce functional recovery in stroke. Cell Transplant. 12(4), 449-454 (2003).
26. Newman MB, Willing AE, Manresa JJ, Davis-Sanberg C, Sanberg PR: Stroke induced migration of human umbilical cord blood: time course and cytokines Stem Cells Dev. 14, 576-586 (2005).
27. Newcomb JD, Ajmo CT, Davis-Sanberg C, Sanberg PR, Pennypacker KR, Willing AE: Timing of cord blood treatment after experimental stroke determines therapeutic efficacy. Cell Transplant. 15(3), 213-223 (2006).
28. Gluckman E, Rocha V, Boyer-Chammard A et al.: Outcome of cord-blood transplantation from related and unrelated donors. N. Engl. J. Med. 337, 373-381 (1997).
29. Couriel D, Caldera H, Champlin R, Komanduri K: Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 101(9), 1936-1946 (2004).
30. Antin JH, Ferrara JL: Cytokine dysregulation and acute graft verus host disease. Blood 80, 2964-2968 (1992).
31. Bradley MB, Cairo M S: Cord blood immunology and stem cell transplantation. Hum. Immunol. 66(5), 431-446 (2005).
32. Barrios C, Brandt C, Berney M, Lambert PH, Siegrist CA: Partial correction of the Th2/Th1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects. Eur. J. Immunol. 26, 2666-2670 (1996).
33. Rainsford E, Reen DJ: Interleukin 10, produced in abundance by human newborn T cells, may be the regulator of increased tolerance associated with cord blood stem cell transplantation. Br. J. Haematol. 116, 702-709 (2002).
34. Buelens C, Willems F, Delvuax A et al.: Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur. J. Immunol. 25, 2668-2672 (1995).
35. Asseman C, Powrie F: Interleukin-10 is a growth factor for a population of regulatory T cells. Gut 42, 157-158 (1998).
36. +-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 105, 750-758 (2005).
37. Kloosterboer FM, van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF: Umbilical cord blood-naive T cells but not adult blood-naive T cells require HLA class II on antigen-presenting cells for allo-immune activation. Hum. Immunol. 65, 328-339 (2004).
38. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C: Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 95, 2484-2490 (2000).
39. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH: Induction of tolerance by IL-10 treated dendritic cells. J. Immunol. 159(10), 4772-4780 (1997).
40. Jang Q, Azuma E, Hirayama M et al.: Functional immaturity of cord blood monocytes as detected by impaired response to hepatocyte growth factor. Pediatr. Int. 43, 334-339 (2001).
41. Theilgaard-Monch K, Raeschou-Jansen K, Palm H et al.: Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts. Bone Marrow Transplant. 28, 1073-1082 (2001).
42. El Marsefy S, Dosquet C, Coudert M-C, Bensussan A, Carosella E, Gluckman E: Study of cord blood natural killer cell suppressor activity. Eur. J. Haematol. 66, 215-220 (2001).
43. Dalle J-H, Menezes J, Wagner E et al.: Characterization of cord blood natural killer cells implications for transplantation and neonatal infections. Pediatr. Res. 57(5), 649-655 (2005).
44. Pan Y, Nastav B, Zhang H, Bretton RH, Panneton WM, Bicknese AR: Engraftment of freshly isolated or cultured human umbilical cord blood cells and the effect of cyclosporin A on the outcome. Exp. Neural. 192(2), 365-372 (2005).
45. Weiss B, Hoffmann M, Anders C et al.: γ-irradiation of blood products following autologous stem cell transplantation: surveillance of the policy of 35 centers Ann. Hematol. 83(1), 44-49 (2004).
46. Ratko TA, Cummings JP, Oberman HA et al.: Evidence-based recommendations for the use of WBC-reduced cellular blood components Transfusion 41, 1310-1319 (2001).
47. Bilgin YM, van de Watering LM, Eijsman L et al.: Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation 109(22), 7755-2760 (2004).
48. Cox JV, Steane E, Cunningham G, Frenkel EP: Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch. Intern. Med. 148, 2485-2489 (1988).
49. Goodnough LT, Brecher M E, Kanter M H, AuBuchon JP: Transfusion medicine blood transfusion. N. Engl. J. Med. 340, 438-447 (1999).
50. Petz LD, Calhoun L. Yam P et al.: Transfusion-associated graft-versus-host disease in immunocompetent patients report of a fatal case associated with transfusion of blood from a second-degree relative and a survey of predisposing factors Transfusion 33, 742-750 (1993).
51. Park KW, Chandhok D: Transfusion-associated complications Int. Anesthesiol. Clin. 42(3), 11-26 (2004).
52. Morris PJ, Ting A, Stocker J: Leukocyte antigensin renal transplantation: 1. The paradox of blood transfusions in renal transplantation. Med. J. Aust. 2, 1088-4090 (1968).
53. Hiesse C, Busson M; Buisson C et al.: Multicenter trial of one HLA-DR-matched or mismatched blood transfusion prior to cadaveric renal transplantation. Kidney Int. 60(1), 341-349 (2001).
54. Holt S, Donaldson H, Hazlehurst G et al.: Acute transplant rejection induced by blood transfusion reaction to the Kidd blood group system. Nephrol. Dial. Transplant. 19(9), 2403-2406 (2004).
55. Puppo, F, Ghio, M, Contini P, Mazzei C, Indiveri F: Fas Fasligand, and transfusion immunomodulation. Transfusion 41, 416-418 (2001).
56. Tartter PI, Steinberg B, Barron DM, Martinelli G: Transfusion history, T cell subsets and natural killer cytotoxicity in patients with colorectal cancer. Vox Sang 56(2), 80-84 (1989).
57. Ford CD, Warnick CT, Sheets S, Quist R, Stevens LE: Blood transfusionslower natural killer cell activity. Transnsplant. Proc 19(1 Pt 2), 1456-1467 (1987).
58. Mincheff M: Changes in donor leukocytes during blood storage. Vox Sang 74. 189-200 (1998).
59. Fadok VA, Bretton D L, Konowal A, Freed PW, Westcott JY, Henson PM: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanism involving TGF-β, PGE2, and PAF. J. Clin. Invest. 101, 890-898 (1998).
60. Bittencourt MC, Perruche S, Contassot E et al.: Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers Blood 98, 224-230 (2001).
61. Wakitani S, Mitsuoka T, Nakamura N, Toritsuka Y, Nakamura Y, Horibe S. Autologous bone marrow stromal cell transplantation for repair of full thickness articular cartilage defects in human patellaer two case reports. Cell Transplant. 13, 595-600 (2004).
62. Henning RJ, Burgos JD, Ondrovic L, Sanberg P, Balis J, Morgan M B. Human umbilical cord blood progenitor cells are attracted to infracted myocardium and significantly reduce myocardial infarction size Cell Transplant. 15(7), 647-658 (2006).
63. Asemus B, Honold J, Schachinger V et al.: Transcoronary transplantation of progenitor cells after myocardial infarction. N. Engl. J. Med. 355(12), 1222-1232 (2006).
64. Nyolczaz N, Gyongyosi M, Beran G et al.: Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) study: a multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous bone marrow cells to patients after cute myocardial infarction. Am. Heart J. 153(2). 212 e1-e7 (2007).
65. Iihohia S, Honmoua O, Houkina K, Hashia K, Kocsis JD: A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemiain adult rats Brain Res 1007, 1-9 (2004).
66. Ohta M, Susuki Y, Noda T et al.: Bone marrow stromal cells infused into the cerebrospinal fluid promote functional recovery of the injured rat spinal cord with reduced cavity formation. Exp. Neurol. 187, 266-278 (2004).
67. Correa P, Felix R, Mendonca ML et al.: Dual-head coincidence gamma camera FDG-PET before and after autologous bone marrow mononuclear cell implantation in ischaemic stroke Eur. J. Nucl. Med. Mol. Imaging 32, 999 (2005).